These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34111559)

  • 61. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
    Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
    J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab.
    Bhola NE; Thomas SM; Freilino M; Joyce S; Sahu A; Maxwell J; Argiris A; Seethala R; Grandis JR
    Clin Cancer Res; 2011 Aug; 17(15):4996-5004. PubMed ID: 21653688
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
    Matsumoto Y; Sakurai H; Kogashiwa Y; Kimura T; Matsumoto Y; Shionome T; Asano M; Saito K; Kohno N
    Head Neck; 2017 Mar; 39(3):476-485. PubMed ID: 27880014
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers.
    Klinghammer K; Keller J; George J; Hoffmann J; Chan EL; Hayman MJ
    Int J Cancer; 2018 Jan; 142(1):156-164. PubMed ID: 28906000
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Differential escape mechanisms in cetuximab-resistant head and neck cancer cells.
    Willey CD; Anderson JC; Trummell HQ; Naji F; de Wijn R; Yang ES; Bredel M; Thudi NK; Bonner JA
    Biochem Biophys Res Commun; 2019 Sep; 517(1):36-42. PubMed ID: 31311651
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Molecular mechanisms of assembly and TRIP13-mediated remodeling of the human Shieldin complex.
    Xie W; Wang S; Wang J; de la Cruz MJ; Xu G; Scaltriti M; Patel DJ
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33597306
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
    Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.
    O'Keefe RA; Bhola NE; Lee DS; Johnson DE; Grandis JR
    PLoS One; 2020; 15(1):e0227261. PubMed ID: 31914141
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.
    Hatakeyama H; Cheng H; Wirth P; Counsell A; Marcrom SR; Wood CB; Pohlmann PR; Gilbert J; Murphy B; Yarbrough WG; Wheeler DL; Harari PM; Guo Y; Shyr Y; Slebos RJ; Chung CH
    PLoS One; 2010 Sep; 5(9):e12702. PubMed ID: 20856931
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab.
    Hartmann S; Neckel N; Seher A; Mutzbauer G; Brands RC; Linz C; Kübler AC; Müller-Richter UD
    Clin Oral Investig; 2016 May; 20(4):759-69. PubMed ID: 26297130
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells.
    Johansson AC; Ansell A; Jerhammar F; Lindh MB; Grénman R; Munck-Wikland E; Östman A; Roberg K
    Mol Cancer Res; 2012 Sep; 10(9):1158-68. PubMed ID: 22809838
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
    Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
    BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α.
    Lu H; Liang K; Lu Y; Fan Z
    Cancer Lett; 2012 Sep; 322(1):78-85. PubMed ID: 22348829
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
    Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
    Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
    Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances
    Zeng L; Beggs RR; Cooper TS; Weaver AN; Yang ES
    Mol Cancer Ther; 2017 Apr; 16(4):591-600. PubMed ID: 28138028
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines.
    Yamatodani T; Ekblad L; Kjellén E; Johnsson A; Mineta H; Wennerberg J
    J Cancer Res Clin Oncol; 2009 Mar; 135(3):395-402. PubMed ID: 18813952
    [TBL] [Abstract][Full Text] [Related]  

  • 80. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.